Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. The company is headquartered in Osaka, Osaka-Fu and currently employs 4,955 full-time employees. The firm is mainly engaged in the research and development, purchasing, manufacturing, sales, and related activities of ethical pharmaceuticals. The firm is engaged in research and development, purchasing, manufacturing, and marketing of pharmaceuticals for the treatment of gram-negative bacterial infections, influenza virus infections, new coronavirus infections, invasive aspergillus infections, complicated urinary tract infections including pyelonephritis, Alzheimer's disease, chronic pain, cancer of the esophagus, bladder, head and neck, solid tumors, and other diseases. The firm provides products and services in Japan, Europe, North America, and other regions.
Le segment de revenus le plus important est Shionogi & Co., Ltd., avec un chiffre d'affaires de Pharmaceutical lors du dernier rapport de résultats. En termes géographiques, United Kingdom est le marché principal pour Shionogi & Co., Ltd., avec un chiffre d'affaires de 245,512,000,000.